{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:18:10Z","timestamp":1788923890797,"version":"build-2803163510"},"reference-count":123,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004748","name":"Mashhad University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004748","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.tice.2025.103164","type":"journal-article","created":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T14:15:25Z","timestamp":1759068925000},"page":"103164","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["CAR T-cell therapy in autoimmune diseases: Opportunities and challenges, with implications for RA"],"prefix":"10.1016","volume":"98","author":[{"given":"Mohamad mahdi","family":"Hojati shargh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Mahmoudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Amir Asef","family":"Agah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Forouzanfar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Javanmardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsane","family":"Fadaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariush","family":"Haghmorad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9371-4170","authenticated-orcid":false,"given":"Seyed-Alireza","family":"Esmaeili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tice.2025.103164_bib1","unstructured":"A Phase, I.I., 2015. Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia [Internet]. 2015a. Available from\u3008https:\/\/clinicaltrials.gov\/study\/NCT02435849\u3009."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/immuno5010006","article-title":"Advances in synthetic immunology for targeted treatment of systemic autoimmune diseases: opportunities, challenges, and future directions","volume":"5","author":"Adytia","year":"2025","journal-title":"Immuno"},{"key":"10.1016\/j.tice.2025.103164_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.cca.2020.11.003","article-title":"Traditional and modern management strategies for rheumatoid arthritis","volume":"512","author":"Akram","year":"2021","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.tice.2025.103164_bib4","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fonc.2024.1398078","article-title":"Overview of infectious complications among CAR T- cell therapy recipients","volume":"14","author":"Arya","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tice.2025.103164_bib5","series-title":"Reviews on New Drug Targets in Age-Related Disorders: Part II","first-page":"87","article-title":"Immunoregulatory effects of tolerogenic probiotics in multiple sclerosis","author":"Atabati","year":"2021"},{"issue":"2","key":"10.1016\/j.tice.2025.103164_bib6","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1016\/S2665-9913(24)00282-0","article-title":"CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series","volume":"7","author":"Auth","year":"2025","journal-title":"Lancet Rheuma"},{"issue":"2","key":"10.1016\/j.tice.2025.103164_bib7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/art.42677","article-title":"Effects of b cell depletion by CD19-Targeted chimeric antigen receptor t cells in a murine model of systemic sclerosis","volume":"76","author":"Avouac","year":"2024","journal-title":"Arthritis Rheuma"},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib8","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2023.2210046","article-title":"Kymriah\u00ae (tisagenlecleucel) - an overview of the clinical development journey of the first approved CAR-T therapy","volume":"19","author":"Awasthi","year":"2023","journal-title":"Hum. Vaccin Immunother."},{"issue":"12","key":"10.1016\/j.tice.2025.103164_bib9","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.ccell.2023.10.002","article-title":"Bringing CAR t cell therapy trials to underserved populations","volume":"41","author":"Badr","year":"2023","journal-title":"Cancer Cell"},{"issue":"5","key":"10.1016\/j.tice.2025.103164_bib10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/CCO.0000000000000869","article-title":"T-cell-engaging antibodies for the treatment of solid tumors: challenges and opportunities","volume":"34","author":"Baeuerle","year":"2022","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.tice.2025.103164_bib11","doi-asserted-by":"crossref","DOI":"10.2174\/0113816128336391241107112957","article-title":"Revolutionizing cancer treatment: unveiling the power of CAR T-cell therapy","author":"Barjasteh","year":"2025","journal-title":"Curr. Pharm. Des."},{"issue":"6","key":"10.1016\/j.tice.2025.103164_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20061283","article-title":"Killing mechanisms of chimeric antigen receptor (CAR) t cells","volume":"20","author":"Benmebarek","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.tice.2025.103164_bib13","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1136\/ard-2023-223952","article-title":"Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR t cells","volume":"82","author":"Bergmann","year":"2023","journal-title":"Ann. Rheum. Dis."},{"issue":"4","key":"10.1016\/j.tice.2025.103164_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002907","article-title":"CAR t cells for treating autoimmune diseases","volume":"9","author":"Blache","year":"2023","journal-title":"RMD Open"},{"issue":"8","key":"10.1016\/j.tice.2025.103164_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16081599","article-title":"Chimeric antigen receptor (CAR) T-Cell therapy in hematologic malignancies: clinical implications and limitations","volume":"16","author":"Bl\u00fcm","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.tice.2025.103164_bib16","doi-asserted-by":"crossref","unstructured":"Bondeelle L., Di Blasi R., Samy L., Aguinaga L., Lorillon G., Bernard S., et al. CAR T cells-associated delayed lung toxicity \u2013 a case series. European Respiratory Journal.56(suppl 64):746.(n.d).","DOI":"10.1183\/13993003.congress-2020.746"},{"issue":"23","key":"10.1016\/j.tice.2025.103164_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13236067","article-title":"T cell engaging immunotherapies, highlighting chimeric antigen receptor (CAR) t cell therapy","volume":"13","author":"De Bousser","year":"2021","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.tice.2025.103164_bib18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamaoncol.2025.0042","article-title":"Key challenges in CAR T-Cell therapy access in community oncology","volume":"11","author":"Byrne","year":"2025","journal-title":"JAMA Oncol."},{"issue":"9","key":"10.1016\/j.tice.2025.103164_bib19","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1073\/pnas.0813101106","article-title":"Control of large, established tumor xenografts with genetically retargeted human t cells containing CD28 and CD137 domains","volume":"106","author":"Carpenito","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.tice.2025.103164_bib20","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.3389\/fonc.2019.01237","article-title":"Understanding the mechanisms of resistance to CAR T-Cell therapy in malignancies","volume":"9","author":"Cheng","year":"2019","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.tice.2025.103164_bib21","doi-asserted-by":"crossref","DOI":"10.1002\/acg2.84","article-title":"TRUCKS, the fourth-generation CAR t cells: current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib22","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13075-024-03451-1","article-title":"Immunological effects of CD19.CAR-T cell therapy in systemic sclerosis: an extended case study","volume":"26","author":"Claus","year":"2024","journal-title":"Arthritis Res. Ther."},{"issue":"10","key":"10.1016\/j.tice.2025.103164_bib23","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1038\/s41409-024-02369-1","article-title":"Challenges and successes in cellular therapies and CAR-T: insights from the 50th EBMT annual meeting","volume":"59","author":"Colman","year":"2024","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.tice.2025.103164_bib24","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br. J. Pharm."},{"issue":"7","key":"10.1016\/j.tice.2025.103164_bib25","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1080\/1744666X.2019.1614915","article-title":"Pathophysiology of systemic sclerosis: current understanding and new insights","volume":"15","author":"Cutolo","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"6","key":"10.1016\/j.tice.2025.103164_bib26","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1136\/ard-2024-225638","article-title":"Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease","volume":"83","author":"Daamen","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib27","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/s41392-025-02168-0","article-title":"Systemic lupus erythematosus: updated insights on the pathogenesis, diagnosis, prevention and therapeutics","volume":"10","author":"Dai","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.tice.2025.103164_bib28","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1006\/mthe.2002.0611","article-title":"A phase II randomized study of HIV-specific T-cell gene therapy in subjects with undetectable plasma viremia on combination antiretroviral therapy","volume":"5","author":"Deeks","year":"2002","journal-title":"Mol. Ther."},{"issue":"3","key":"10.1016\/j.tice.2025.103164_bib29","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf' allogeneic CAR t cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"issue":"6295","key":"10.1016\/j.tice.2025.103164_bib30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.aaf6756","article-title":"Reengineering chimeric antigen receptor t cells for targeted therapy of autoimmune disease","volume":"353","author":"Ellebrecht","year":"2016","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib31","article-title":"Molecular and cellular pathways contributing to joint damage in rheumatoid arthritis","volume":"2020","author":"Fang","year":"2020","journal-title":"Mediat. Inflamm."},{"issue":"10","key":"10.1016\/j.tice.2025.103164_bib32","first-page":"591","article-title":"Global epidemiology of rheumatoid arthritis","volume":"18","author":"Finckh","year":"2022","journal-title":"Nat. Rev. Rheuma"},{"key":"10.1016\/j.tice.2025.103164_bib33","first-page":"343","article-title":"Biological therapies for rheumatoid arthritis: an overview for the clinician","volume":"15","author":"Findeisen","year":"2021","journal-title":"Biologics"},{"issue":"6","key":"10.1016\/j.tice.2025.103164_bib34","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in t cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.tice.2025.103164_bib35","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor t cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.tice.2025.103164_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1403145","article-title":"Comparing 2-day vs 3-day flu-CY lymphodepleting regimens for CD19 CAR T-cell therapy in patients with non-hodgkin's lymphoma","volume":"15","author":"Frame","year":"2024","journal-title":"Front Immunol."},{"key":"10.1016\/j.tice.2025.103164_bib37","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/1742-2094-9-112","article-title":"CAR\/FoxP3-engineered t regulatory cells target the CNS and suppress EAE upon intranasal delivery","volume":"9","author":"Fransson","year":"2012","journal-title":"J. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.tice.2025.103164_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s40290-022-00428-w","article-title":"Barriers to chimeric antigen receptor T-Cell (CAR-T) therapies in clinical practice","volume":"36","author":"Gajra","year":"2022","journal-title":"Pharm. Med."},{"issue":"6","key":"10.1016\/j.tice.2025.103164_bib39","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1097\/BOR.0000000000000555","article-title":"Antisynthetase syndrome pathogenesis: knowledge and uncertainties","volume":"30","author":"Gallay","year":"2018","journal-title":"Curr. Opin. Rheuma."},{"issue":"2","key":"10.1016\/j.tice.2025.103164_bib40","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000191","article-title":"In the eye of the storm: Immune-mediated toxicities associated with CAR-T cell therapy","volume":"3","author":"Garcia Borrega","year":"2019","journal-title":"Hemasphere"},{"key":"10.1016\/j.tice.2025.103164_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2024.114075","article-title":"Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review","volume":"205","author":"G\u00e9raud","year":"2024","journal-title":"Eur. J. Cancer"},{"issue":"2","key":"10.1016\/j.tice.2025.103164_bib42","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR t cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat. Biomed. Eng."},{"issue":"7","key":"10.1016\/j.tice.2025.103164_bib43","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","article-title":"Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study","volume":"22","author":"Granit","year":"2023","journal-title":"Lancet Neurol."},{"issue":"15","key":"10.1016\/j.tice.2025.103164_bib44","doi-asserted-by":"crossref","first-page":"3370","DOI":"10.1096\/fasebj.6.15.1464371","article-title":"Endowing t cells with antibody specificity using chimeric t cell receptors","volume":"6","author":"Gross","year":"1992","journal-title":"Faseb J."},{"issue":"24","key":"10.1016\/j.tice.2025.103164_bib45","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","article-title":"Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity","volume":"86","author":"Gross","year":"1989","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"2","key":"10.1016\/j.tice.2025.103164_bib46","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T Cell-Mediated B-Cell depletion in central nervous system autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"issue":"3","key":"10.1016\/j.tice.2025.103164_bib47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/nrg.2015.33","article-title":"Autoimmune diseases - connecting risk alleles with molecular traits of the immune system","volume":"17","author":"Gutierrez-Arcelus","year":"2016","journal-title":"Nat. Rev. Genet"},{"key":"10.1016\/j.tice.2025.103164_bib48","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fimmu.2024.1461756","article-title":"Overview of mechanisms and novel therapies on rheumatoid arthritis from a cellular perspective","volume":"15","author":"Han","year":"2024","journal-title":"Front. Immunol."},{"issue":"16","key":"10.1016\/j.tice.2025.103164_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168996","article-title":"CAR T-Cell therapy in hematological malignancies","volume":"22","author":"Haslauer","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tice.2025.103164_bib50","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1146\/annurev.immunol.18.1.975","article-title":"gamma][delta] cells: a right time and a right place for a conserved third way of protection","volume":"18","author":"Hayday","year":"2000","journal-title":"Annu Rev. Immunol."},{"key":"10.1016\/j.tice.2025.103164_bib51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clicom.2025.04.001","article-title":"Persistent hypogammaglobulinemia after rituximab therapy in pediatric patients, prevalence and clinical outcomes","volume":"7","author":"H\u00f6ppener","year":"2025","journal-title":"Clin. Immunol. Commun."},{"issue":"5","key":"10.1016\/j.tice.2025.103164_bib52","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard-2023-224878","article-title":"Proinflammatory phenotype of B10 and B10pro cells elicited by TNF-\u03b1 in rheumatoid arthritis","volume":"83","author":"Hu","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"11","key":"10.1016\/j.tice.2025.103164_bib53","first-page":"1082","article-title":"Real-World analysis of barriers to timely administration of chimeric antigen receptor t cell (CAR T) therapy in diffuse large B-cell lymphoma","volume":"30","author":"Hu","year":"2024","journal-title":"Transpl. Cell Ther."},{"issue":"4","key":"10.1016\/j.tice.2025.103164_bib54","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.tice.2025.103164_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.3981","article-title":"Tolerogenic probiotics lactobacillus delbrueckii and lactobacillus rhamnosus promote anti-inflammatory profile of macrophages-derived monocytes of newly diagnosed patients with systemic lupus erythematosus","volume":"42","author":"Javanmardi","year":"2024","journal-title":"Cell Biochem. Funct."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib56","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-025-01737-8","article-title":"Recent advances in universal chimeric antigen receptor t cell therapy","volume":"18","author":"Jiang","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.tice.2025.103164_bib57","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/s41423-020-0472-1","article-title":"Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus","volume":"18","author":"Jin","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"6382","key":"10.1016\/j.tice.2025.103164_bib58","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR t cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.tice.2025.103164_bib59","doi-asserted-by":"crossref","first-page":"208","DOI":"10.14791\/btrt.2024.0037","article-title":"Lymphodepletion in chimeric antigen receptor T-Cell therapy for solid tumors: a focus on brain tumors","volume":"12","author":"Ju","year":"2024","journal-title":"Brain Tumor Res. Treat."},{"issue":"482","key":"10.1016\/j.tice.2025.103164_bib60","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aav1648","article-title":"Sustained b cell depletion by CD19-targeted CAR t cells is a highly effective treatment for murine lupus","volume":"11","author":"Kansal","year":"2019","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.tice.2025.103164_bib61","article-title":"Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis","volume":"2010","author":"Katchamart","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib62","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s00296-024-05772-5","article-title":"Safety and efficacy of CAR-T cell therapy in patients with autoimmune diseases: a systematic review","volume":"45","author":"Kattamuri","year":"2025","journal-title":"Rheuma Int."},{"issue":"5","key":"10.1016\/j.tice.2025.103164_bib63","first-page":"327","article-title":"T cell immune response to influenza vaccination when administered prior to and following autologous chimeric antigen Receptor-Modified t cell therapy","volume":"31","author":"Kinoshita","year":"2025","journal-title":"Transpl. Cell Ther."},{"issue":"7","key":"10.1016\/j.tice.2025.103164_bib64","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41584-022-00793-5","article-title":"Mechanisms of joint destruction in rheumatoid arthritis \u2014 immune cell\u2013fibroblast\u2013bone interactions","volume":"18","author":"Komatsu","year":"2022","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.tice.2025.103164_bib65","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.omtm.2016.12.006","article-title":"Global manufacturing of CAR t cell therapy","volume":"4","author":"Levine","year":"2017","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.tice.2025.103164_bib66","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.tice.2025.103164_bib67","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/ard-2023-224875","article-title":"CD19-targeting CAR t cells protect from ANCA-induced acute kidney injury","volume":"83","author":"Lodka","year":"2024","journal-title":"Ann. Rheum. Dis."},{"issue":"5","key":"10.1016\/j.tice.2025.103164_bib68","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2165\/00003495-200666050-00004","article-title":"B cell-targeted therapy for rheumatoid arthritis: an update on the evidence","volume":"66","author":"Looney","year":"2006","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.tice.2025.103164_bib69","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR t cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"issue":"3","key":"10.1016\/j.tice.2025.103164_bib70","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/BOR.0000000000000496","article-title":"Recent advances in the treatment of rheumatoid arthritis","volume":"30","author":"Mahajan","year":"2018","journal-title":"Curr. Opin. Rheuma"},{"issue":"10","key":"10.1016\/j.tice.2025.103164_bib71","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tice.2025.103164_bib72","doi-asserted-by":"crossref","DOI":"10.1017\/erm.2021.32","article-title":"Chimeric antigen receptor engineered t cells and their application in the immunotherapy of solid tumours","volume":"24","author":"Mao","year":"2022","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.tice.2025.103164_bib73","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.640082","article-title":"Allogeneic CAR t cells: an alternative to overcome challenges of CAR t cell therapy in glioblastoma","volume":"12","author":"Mart\u00ednez Bedoya","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.tice.2025.103164_bib74","doi-asserted-by":"crossref","first-page":"175","DOI":"10.5415\/apallergy.0000000000000128","article-title":"Immunological mechanisms of tolerance: central, peripheral and the role of t and b cells","volume":"13","author":"Meng","year":"2023","journal-title":"Asia Pac. Allergy"},{"key":"10.1016\/j.tice.2025.103164_bib75","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221142133","article-title":"CAR T-cell therapy for follicular lymphoma and mantle cell lymphoma","volume":"13","author":"Mohty","year":"2022","journal-title":"Ther. Adv. Hematol."},{"issue":"2","key":"10.1016\/j.tice.2025.103164_bib76","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"issue":"8","key":"10.1016\/j.tice.2025.103164_bib77","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-Cell therapy in autoimmune disease - a case series with Follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.tice.2025.103164_bib78","doi-asserted-by":"crossref","first-page":"2182","DOI":"10.1182\/bloodadvances.2024012885","article-title":"Reinfusion of CD19 CAR t cells for relapse prevention and treatment in children with acute lymphoblastic leukemia","volume":"8","author":"Myers","year":"2024","journal-title":"Blood Adv."},{"issue":"6","key":"10.1016\/j.tice.2025.103164_bib79","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1182\/blood.2023021243","article-title":"Three-year follow-up analysis of axicabtagene ciloleucel in relapsed\/refractory indolent non-Hodgkin lymphoma (ZUMA-5)","volume":"143","author":"Neelapu","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tice.2025.103164_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1062376","article-title":"Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?","volume":"14","author":"Noto","year":"2023","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.tice.2025.103164_bib81","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41584-020-0413-5","article-title":"Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes","volume":"16","author":"Nygaard","year":"2020","journal-title":"Nat. Rev. Rheumatol."},{"issue":"8","key":"10.1016\/j.tice.2025.103164_bib82","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/art.38012","article-title":"Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial","volume":"65","author":"O'Dell","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.tice.2025.103164_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2023.101136","article-title":"Access to CAR T-cell therapy: focus on diversity, equity and inclusion","volume":"63","author":"Odstrcil","year":"2024","journal-title":"Blood Rev."},{"issue":"24","key":"10.1016\/j.tice.2025.103164_bib84","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2023.8753","article-title":"CD19-Targeting CAR t cells for myositis and interstitial lung disease associated with antisynthetase syndrome","volume":"329","author":"Pecher","year":"2023","journal-title":"Jama"},{"issue":"18","key":"10.1016\/j.tice.2025.103164_bib85","doi-asserted-by":"crossref","first-page":"4133","DOI":"10.1182\/blood-2011-12-400044","article-title":"Tumor-targeted t cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning","volume":"119","author":"Pegram","year":"2012","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.tice.2025.103164_bib86","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/s41581-023-00720-1","article-title":"Pathogenesis of autoimmune disease","volume":"19","author":"Pisetsky","year":"2023","journal-title":"Nat. Rev. Nephrol."},{"issue":"374","key":"10.1016\/j.tice.2025.103164_bib87","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR t cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med"},{"issue":"10","key":"10.1016\/j.tice.2025.103164_bib88","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1002\/art.11223","article-title":"Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis","volume":"48","author":"Rantap\u00e4\u00e4-Dahlqvist","year":"2003","journal-title":"Arthritis Rheum."},{"issue":"2","key":"10.1016\/j.tice.2025.103164_bib89","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s40744-017-0073-3","article-title":"Treatment with biologicals in rheumatoid arthritis: an overview","volume":"4","author":"Rein","year":"2017","journal-title":"Rheuma Ther."},{"issue":"7","key":"10.1016\/j.tice.2025.103164_bib90","first-page":"418","article-title":"Mechanisms of resistance and treatment of relapse after CAR T-cell therapy for large B-cell lymphoma and multiple myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transpl. Cell Ther."},{"key":"10.1016\/j.tice.2025.103164_bib91","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.689698","article-title":"Etiology and risk factors for rheumatoid arthritis: a State-of-the-Art review","volume":"8","author":"Rom\u00e3o","year":"2021","journal-title":"Front. Med."},{"issue":"125","key":"10.1016\/j.tice.2025.103164_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003504","article-title":"Treating human autoimmunity: current practice and future prospects","volume":"4","author":"Rosenblum","year":"2012","journal-title":"Sci. Transl. Med."},{"issue":"4","key":"10.1016\/j.tice.2025.103164_bib93","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib94","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced t lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.tice.2025.103164_bib95","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/phar.1900","article-title":"Chimeric antigen receptor t cells in hematologic malignancies","volume":"37","author":"Shank","year":"2017","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.tice.2025.103164_bib96","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.omto.2023.04.003","article-title":"Durable remission related to CAR-T persistence in R\/R B-ALL and long-term persistence potential of prime CAR-T","volume":"29","author":"Shiqi","year":"2023","journal-title":"Mol. Ther. Oncolytics"},{"issue":"15","key":"10.1016\/j.tice.2025.103164_bib97","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib98","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41392-024-01952-8","article-title":"Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders","volume":"9","author":"Song","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.tice.2025.103164_bib99","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40744-024-00674-1","article-title":"Drug persistence and incidence of active tuberculosis of tumor necrosis factor alpha inhibitors versus tocilizumab as the First-Line biological treatment in patients with rheumatoid arthritis: a nationwide Population-Based retrospective cohort analysis","volume":"11","author":"So","year":"2024","journal-title":"Rheuma Ther."},{"key":"10.1016\/j.tice.2025.103164_bib100","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther. Adv. Infect. Dis."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib101","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1093\/rheumatology\/kead330","article-title":"Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies","volume":"63","author":"Taubmann","year":"2024","journal-title":"Rheumatology"},{"issue":"6","key":"10.1016\/j.tice.2025.103164_bib102","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1182\/blood-2007-12-128843","article-title":"Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific t cells","volume":"112","author":"Till","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.tice.2025.103164_bib103","unstructured":"Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA) [Internet]. 2018. Available from: \u3008https:\/\/clinicaltrials.gov\/study\/NCT03570892\u3009."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib104","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: next-generation CAR t cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.tice.2025.103164_bib105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.omtm.2019.11.018","article-title":"Optimizing CAR-T cell manufacturing processes during pivotal clinical trials","volume":"16","author":"Tyagarajan","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"21","key":"10.1016\/j.tice.2025.103164_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242115688","article-title":"CAR-T cell therapy: from the shop to cancer therapy","volume":"24","author":"Uscanga-Palomeque","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"17","key":"10.1016\/j.tice.2025.103164_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/cells12172192","article-title":"Systemic inflammatory disorders, immunosuppressive treatment and increase risk of head and neck Cancers-A narrative review of potential physiopathological and biological mechanisms","volume":"12","author":"Vale","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib108","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/imr.12829","article-title":"Autoantibodies and b cells: the ABC of rheumatoid arthritis pathophysiology","volume":"294","author":"Volkov","year":"2020","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.tice.2025.103164_bib109","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000516642","article-title":"T-Cell immune imbalance in rheumatoid arthritis is associated with alterations in NK cells and NK-Like t cells expressing CD38","volume":"14","author":"Wang","year":"2022","journal-title":"J. Innate Immun."},{"issue":"10","key":"10.1016\/j.tice.2025.103164_bib110","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR t cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.tice.2025.103164_bib111","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1182\/blood-2024-201125","article-title":"Efficacy and safety of inaticabtagene autoleucel in children with Relapsed\/Refractory (R\/R) B-cell acute lymphoblastic leukemia in China","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"18","key":"10.1016\/j.tice.2025.103164_bib112","doi-asserted-by":"crossref","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","article-title":"Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis","volume":"187","author":"Wang","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib113","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4049\/jimmunol.2100643","article-title":"CD8(+) t cells expressing an HLA-DR1 chimeric antigen receptor target autoimmune CD4(+) t cells in an Antigen-Specific manner and inhibit the development of autoimmune arthritis","volume":"208","author":"Whittington","year":"2022","journal-title":"J. Immunol."},{"key":"10.1016\/j.tice.2025.103164_bib114","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1241474","article-title":"Double-negative-2 b cells are the major synovial plasma cell precursor in rheumatoid arthritis","volume":"14","author":"Wing","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tice.2025.103164_bib115","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.3389\/fimmu.2019.02664","article-title":"Mechanisms of relapse after CD19 CAR T-Cell therapy for acute lymphoblastic leukemia and its prevention and treatment strategies","volume":"10","author":"Xu","year":"2019","journal-title":"Front Immunol."},{"issue":"76","key":"10.1016\/j.tice.2025.103164_bib116","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abo0777","article-title":"Antigen-specific depletion of CD4(+) t cells by CAR t cells reveals distinct roles of higher- and lower-affinity TCRs during autoimmunity","volume":"7","author":"Yi","year":"2022","journal-title":"Sci. Immunol."},{"issue":"null","key":"10.1016\/j.tice.2025.103164_bib117","doi-asserted-by":"crossref","first-page":"10953","DOI":"10.2147\/JIR.S530754","article-title":"Role of Interleukin-6 in rheumatoid Arthritis-Associated interstitial lung disease: focus on the JAK\/STAT pathway and macrophage polarization","volume":"18","author":"Yu","year":"2025","journal-title":"J. Inflamm. Res."},{"issue":"6","key":"10.1016\/j.tice.2025.103164_bib118","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","article-title":"T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant b cells","volume":"4","author":"Zah","year":"2016","journal-title":"Cancer Immunol. Res"},{"issue":"7","key":"10.1016\/j.tice.2025.103164_bib119","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1136\/annrheumdis-2016-209991","article-title":"Presence of anticitrullinated protein antibodies in a large population-based cohort from the Netherlands","volume":"76","author":"van Zanten","year":"2017","journal-title":"Ann. Rheum. Dis."},{"issue":"2","key":"10.1016\/j.tice.2025.103164_bib120","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2020-217844","article-title":"In vitro elimination of autoreactive b cells from rheumatoid arthritis patients by universal chimeric antigen receptor t cells","volume":"80","author":"Zhang","year":"2021","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib121","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1186\/s12889-024-19290-3","article-title":"Age-standardized incidence, prevalence, and mortality rates of autoimmune diseases in adolescents and young adults (15\u201339 years): an analysis based on the global burden of disease study 2021","volume":"24","author":"Zhao","year":"2024","journal-title":"BMC Public Health"},{"key":"10.1016\/j.tice.2025.103164_bib122","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1476859","article-title":"CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives","volume":"15","author":"Zhou","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.tice.2025.103164_bib123","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct. Target. Ther."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004081662500446X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004081662500446X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T04:18:59Z","timestamp":1785298739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004081662500446X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":123,"alternative-id":["S004081662500446X"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2025.103164","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR T-cell therapy in autoimmune diseases: Opportunities and challenges, with implications for RA","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2025.103164","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103164"}}